The first new drug for Alzheimer’s disease in nearly 20 years cleared a big hurdle yesterday, offering fresh hope for patients in Britain and millions worldwide. US regulators gave conditional approval for the use of aducanumab, which targets proteins in the brain to slow the progress of the disease. SponsoredExisting drugs for Alzheimer’s treat the symptoms of the disease. Aducanumab is the first to win regulatory approval that targets what is believed to be the underlying cause. Bart De Strooper, director of the UK Dementia Research Institute, said: “With no effective therapies currently available to modify the

Source: The Times June 07, 2021 15:50 UTC